Thrombin Generation during Cardiac Surgery: Is Heparin the Ideal Anticoagulant?

Summary

Blood samples were collected from 43 patients undergoing elective cardiac surgery to determine the extent of thrombin generation and inhibition in patients when receiving heparin while undergoing cardiopulmonary bypass (CPB). Plasma prothrombin fragment F_{1 + 2} and thrombin-antithrombin III (TAT) levels were measured as markers of thrombin generation and inhibition, respectively. Both F_{1 + 2} and TAT levels increased significantly during the course of CPB despite the heparin causing significant systemic anticoagulation, i.e. the activated coagulation time (ACT) was prolonged to greater than 400 s throughout the entire surgical procedure. The extent of thrombin generation increased with time on CPB but did not differ between patients receiving normothermic and hypothermic cardioplegia during CPB. Furthermore, thrombin generation increased following the neutralization of the heparin with protamine sulphate, and continued to be elevated significantly 24 h post surgery. The observation that high dose heparin did not prevent thrombin generation during CPB, is consistent with previous experimental studies demonstrating that thrombin bound to fibrin or other surfaces (e.g. the CPB conduit) is resistant to antithrombin III/heparin inhibition, and thus able to facilitate further thrombin generation. The observation that thrombin generation continued to be elevated post surgery i.e. 24 h after neutralizing the heparin with protamine sulphate, suggests that the high dose heparin did not inhibit effectively all of the thrombin that had been generated. Thus, CPB patients may be at risk not only of bleeding and other side-effects associated with the acute use of high dose heparin, but may also be at risk of further thrombosis-related events either acutely or chronically.

• References

• 1 Young JA, Kisher T, Doty DB. Adequate anticoagulation during cardiopulmonary bypass determined by activated coagulation time and appearance of fibrin monomer. Ann Thorac Surg 1978; 26: 231-240
• 2 Schwartz BS. Heparin: What is it?. How does it work?. Clin Cardiol 1990; 13: 112-115
• 3 Hirsh J. Mechanism of action and monitoring of anticoagulants. Semin Thromb Hemostas 1986; 12: 1-11
• 4 Ofosu FA, Gray E. Mechanisms of action of heparin: applications to the development of derivatives of heparin and heparinoids with antithrombotic potential. Semin Thromb Hemostas 1988; 14: 9-17
• 5 Hynes TM, Hull R, Weg JG. Antithrombotic therapy of venous thromboembolic disease. Chest 1986; 89: 26S-35S
• 6 Ferraris VA, Colonel MC, Gildorin V. Predictors of excessive blood use after coronary artery bypass grafting. J Thorac Cardiovasc Surg 1989; 98: 492-497
• 7 Chong BH, Fawaz I, Chesterman CW, Berndt MC. Heparin-induced thrombocytopenia: mechanism of interaction of the heparin-depenent antibody with platelets. Br J Haematol 1989; 73: 235-240
• 8 Hogg DJ, Jackson CM. Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: Implications for heparin efficacy. Proc Natl Acad Sci 1989; 86: 3619-3623
• 9 Bar-Shavit R, Eldor A, Vlodavsky I. Binding of thrombin to subendothelial extracellular matrix. J Clin Invest 1989; 84: 1096-1104
• 10 Okwusidi JI, Anvari N, Kulczycky M, Blajchman MA, Buchanan MR, Ofosu FA. Fibrin moderates the catalytic action of heparin but not that of dermatan sulfate on thrombin inhibition in human plasma. J Lab Clin Med 1991; 117: 359-364
• 11 Okwusidi JI, Falcone M, Van Ryn-McKenna J, Hirsh J, Ofosu FA, Buchanan MR. In vivo catalysis of thrombin inhibition by antithrombin III or heparin cofactor II and antithrombotic effect: differential effects of unfractionated heparin and dermatan sulphate. Thromb Haemorrh Disorders 1990; 1: 77-80
• 12 Umlas J, Taff RH, Gauvin G, Swierk P. Anticoagulant monitoring and neutralization during open heart surgery – a rapid method for measuring heparin and calculating safe reduced protamine doses. Anesth Analg 1983; 62: 1095-1099
• 13 Pelzer H, Schwartz A, Heimburger N. Determination of thrombin-antithrombin III complex in plasma with an enzyme-linked immunosorbant assay. Thromb Haemostas 1988; 59: 101-106
• 14 Pelzer H, Schwartz A, Stuber W. Determination of human prothrombin activation fragment F_{1 + 2} in plasma with an antibody against a synthetic peptide. Thromb Haemostas 1991; 65: 153-159
• 15 Minitab. MINITAB Reference Manual, Minitab Inc. State College, PA 1988
• 16 Pindur G, Kohler M, Wenzl E. Thrombin-generation inhibition in the presence of unfractionated heparin and low molecular heparin. Thromb Haemorrh Disorders 1992; 5: 37-41
• 17 Brill-Edwards P, Van Ryn-McKenna J, Cai L, Ofosu FA, Buchanan MR. Prevention of thrombus growth by antithrombin III-dependent and two direct thrombin inhibitors in rabbits: implications for antithrombotic therapy. Thromb Haemostas 1992; 68: 563-569
• 18 Van Ryn-McKenna J, Merk H, Müller TH, Buchanan MR, Eisert WG. The effects of heparin and annexin V on fibrin accretion after injury in jugular veins of rabbits. Thromb Haemostas 1993; 69: 227-230